”Dr. Itescu reiterated that the Company expects to file this quarter the Biologics License Application(BLA) resubmission with the United States Food and Drug Administration (FDA) for its lead productcandidate Ryoncil®(remestemcel-L) in the treatment of steroid-refractory acute graft versus hostdisease, with potential approval in the second half of CY2024”
@Pledge … maybe no one watered the plant!sssh, words are cheap - reiterated no less
banter and General Discussion, page-9996
-
- There are more pages in this discussion • 2,150 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.040(3.16%) |
Mkt cap ! $1.490B | |||
| Open | High | Low | Value | Volume |
| $1.28 | $1.32 | $1.26 | $3.433M | 2.652M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39558 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 21776 | 3 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |